Sort by: after hours % change | delayed % change | gain open | gain high | gain close | publishing date
tags : Vaccine crawled date : 2021 - 05 - 27 save search
Sanofi and GSK Launch Late-Stage Trial for COVID-19 Vaccine Candidate
Published: 2021-05-27 (Crawled : 16:00) - biospace.com/
SNY | News | $46.34 2.09% 620K
|
Health Technology
|
| O: -0.5%
H: 0.32%
C: -1.27%
covid vaccine trial covid-19
Will COVID-19 Vaccines Need a Booster? CDC Will Meet to Decide
Published: 2021-05-27 (Crawled : 15:00) - biospace.com/
JNJ | News | $146.39 0.45% 1.8M
|
Health Technology
|
| O: 0.11%
H: 0.54%
C: -0.27%
covid vaccine covid-19
Moderna Highlights Advances in Platform Science and Innovative Vaccine Research at Fourth Annual Science Day
Published: 2021-05-27 (Crawled : 13:00) - biospace.com/
MRNA S | $102.68 0.67% 640K
|
Health Technology
|
| O: -0.79%
H: 3.33%
C: 3.07%
vaccine research
Dynavax Announces Agreement with Bavarian Nordic for Commercialization of HEPLISAV B®, a Two Dose Adult Hepatitis B Adjuvanted Vaccine, in Germany
Published: 2021-05-27 (Crawled : 13:00) - biospace.com/
JNJ | News | $146.39 0.45% 1.8M
|
Health Technology
|
| O: 0.11%
H: 0.54%
C: -0.27%
DVAX | $11.59 2.21% 490K
|
Health Technology
|
| O: 1.91%
H: 4.87%
C: 3.75%
hepatitis commercialization vaccine germany
Okinawa City Chooses SAP and Qualtrics to Put Residents at the Center of Vaccine Operations
Published: 2021-05-27 (Crawled : 12:00) - biospace.com/
XM 4 | $18.14 0.03% 0
|
|
| O: -0.3%
H: 1.28%
C: 0.36%
SAP | News | $176.95 -0.95% 200K
|
Technology Services
|
| O: -1.3%
H: 0.03%
C: -0.97%
vaccine
Bavarian Nordic Announces Marketing and Distribution Agreement with Dynavax to Launch HEPLISAV B® Hepatitis B Vaccine in Germany
Published: 2021-05-27 (Crawled : 06:00) - globenewswire.com
JNJ | News | $146.39 0.45% 1.8M
|
Health Technology
|
| O: 0.11%
H: 0.54%
C: -0.27%
DVAX | $11.59 2.21% 490K
|
Health Technology
|
| O: 1.91%
H: 4.87%
C: 3.75%
hepatitis vaccine distribution germany
Sanofi and GSK initiate global Phase 3 clinical efficacy study of COVID-19 vaccine candidate
Published: 2021-05-27 (Crawled : 06:00) - globenewswire.com
JNJ | News | $146.39 0.45% 1.8M
|
Health Technology
|
| O: 0.11%
H: 0.54%
C: -0.27%
SNY | News | $46.34 2.09% 620K
|
Health Technology
|
| O: -0.5%
H: 0.32%
C: -1.27%
covid vaccine phase 3 covid-19
Ocugen On Track to Submit Emergency Use Authorization Application to U.S. FDA for its COVID-19 Vaccine Candidate, COVAXIN™
Published: 2021-05-27 (Crawled : 01:00) - globenewswire.com
OCGN | News A | $1.295 -1.89% 1.8M
|
Health Technology
|
| O: 0.91%
H: 13.32%
C: 12.68%
covid fda vaccine merge authorized application emergency use authorization
Gainers vs Losers
| 79% | 21% |
Top 10 Gainers
AGBA | News | $1.22 205.0% 86M
|
Finance
EGOX | $0.0606 68.33% 250M
|
NVFY | $3.45 63.51% 20M
|
Consumer Durables
CHRO | $1.66 35.51% 70K
|
n/a
INDO | $5.43 33.09% 10M
|
Energy Minerals
ZCMD | $1.86 28.28% 29M
|
Commercial Services
PAPL | $2.07 26.22% 550K
|
RWOD | $10.08 26.05% 5.6M
|
n/a
AULT | $0.3022 24.82% 51M
|
Manufacturing
HUSA 4 | $2.07 23.95% 2.1M
|
Energy Minerals
Your saved searches
Save your searches and get alerts when important news are released.